Is 50 cent the price of the optimal copayment? - a qualitative study of patient opinions and attitudes in response to a 50 cent charge on prescription drugs in a publicly funded health system in Ireland

Show simple item record

dc.contributor.author Sinnott, Sarah-Jo
dc.contributor.author Guinane, Marie
dc.contributor.author Whelton, Helen
dc.contributor.author Byrne, Stephen
dc.date.accessioned 2016-02-25T16:59:55Z
dc.date.available 2016-02-25T16:59:55Z
dc.date.issued 2013-01-10
dc.identifier.citation SINNOTT, S.-J., GUINANE, M., WHELTON, H. & BYRNE, S. 2013. Is 50 cent the price of the optimal copayment? - a qualitative study of patient opinions and attitudes in response to a 50 cent charge on prescription drugs in a publicly funded health system in Ireland. BMC Health Services Research, 13:16, 1-9. http://dx.doi.org/10.1186/1472-6963-13-16 en
dc.identifier.volume 13 en
dc.identifier.startpage 1 en
dc.identifier.endpage 9 en
dc.identifier.issn 1472-6963
dc.identifier.uri http://hdl.handle.net/10468/2398
dc.identifier.doi 10.1186/1472-6963-13-16
dc.description.abstract Background: A 50 cent prescription levy was introduced in 2010 on the General Medical Services (GMS) scheme (Irish public health insurance). This study sought to examine patient attitudes and opinions surrounding the 50 cent copayment. Given the small momentary value of the prescription fee, these results are of interest to policymakers internationally who wish to reduce copayments rather than abolish them. Methods: A qualitative research design was used; semi structured interviews were carried out. Twenty four GMS eligible participants were interviewed in 23 interviews. Fifteen females and 9 males took part. Ages varied from 31- >70 years. Patients were invited to be interviewed in both independent and chain community pharmacies in three types of setting; 1) a socially deprived urban area, 2) a suburban affluent area and 3) a rural area. The Framework method was used for data management and analysis using QSR International’s NVivo 9.2 qualitative data analysis software. The “Francis method” was used to test for data saturation. Results: Results are of interest to the Irish context and also at a broader international level. Patients were mostly accepting of the prescription levy with some reservations concerning an increased price and the way in which generated revenue would be used by government. Participants identified waste of prescription drugs at the hand of patients (moral hazard), but there was discordant opinion on whether the 50 cent copayment would halt this moral hazard. Interviewees felt the levy was affordable, albeit some may suffer a financial impact more than others. Conclusions: This qualitative study gives important insights into the experiences of GMS patients with regard to the prescription levy. Information regarding the appropriateness of a 50 cent copayment as a symbolic copayment needs to be confirmed by quantitative analysis. Further insight is required from a younger population. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher BioMed Central Ltd. en
dc.rights © Sinnott et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.rights.uri http://​creativecommons.​org/​licenses/​by/​2.​0 en
dc.subject Qualitative research en
dc.subject Copayment en
dc.subject Health policy en
dc.subject Adherence en
dc.subject Ireland en
dc.subject Cost en
dc.subject Impact en
dc.subject Medication en
dc.subject Medicines en
dc.subject Adults en
dc.subject Insurance en
dc.subject Australia en
dc.subject Services en
dc.subject Benefits en
dc.title Is 50 cent the price of the optimal copayment? - a qualitative study of patient opinions and attitudes in response to a 50 cent charge on prescription drugs in a publicly funded health system in Ireland en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Stephen Byrne, Pharmacy, University College Cork, Cork, Ireland. +353-21-490-3000 Email: stephen.byrne@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.description.status Peer reviewed en
dc.identifier.journaltitle BMC Health Services Research en
dc.internal.IRISemailaddress stephen.byrne@ucc.ie en
dc.identifier.articleid 16


Files in this item

This item appears in the following Collection(s)

Show simple item record

© Sinnott et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Except where otherwise noted, this item's license is described as © Sinnott et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement